Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2017

The collaboration revenue the Company earned from Sanofi is detailed below:



	Year Ended December 31,
Sanofi Collaboration Revenue	2017			2016			2015
Antibody:
Reimbursement of Regeneron research and development expenses	$	508,364		$	564,900		$	735,439
Reimbursement of Regeneron commercialization-related expenses	368,859			305,947			155,271
Regeneron's share of losses in connection with commercialization of antibodies	(442,610		)	(459,058		)	(240,042		)
Other	119,076			28,379			12,322
Total Antibody	553,689			440,168			662,990
Immuno-oncology:
Reimbursement of Regeneron research and development expenses	239,981			138,497			39,961
Other	83,523			80,000			40,000
Total Immuno-oncology	323,504			218,497			79,961
ZALTRAP:
Reimbursement of Regeneron research and development expenses	—			—			686
Other	—			—			15,236
Total ZALTRAP	—			—			15,922
	$	877,193		$	658,665		$	758,873

Other selected financial information in connection with the Company's collaboration agreements with Sanofi is as follows:

The collaboration revenue the Company earned from Bayer is detailed below:



	Year Ended December 31,
Bayer Collaboration Revenue	2017		2016		2015
EYLEA:
Regeneron's net profit in connection with commercialization of EYLEA outside the United States	$	802,298	$	649,232	$	466,667
Sales milestones	—		—		15,000
Reimbursement of Regeneron EYLEA development expenses	13,325		9,010		8,887
Other	58,634		52,527		69,466
Total EYLEA	874,257		710,769		560,020
Ang2 antibody and PDGFR-beta antibody:
Reimbursement of development expenses	17,841		18,327		10,075
Other	45,954		15,174		10,393
Total Ang2 antibody and PDGFR-beta antibody	63,795		33,501		20,468
	$	938,052	$	744,270	$	580,488

Deferred revenue in connection with the Company's collaboration agreements with Bayer is as follows: